Neuroinflammation and J2 prostaglandins: Linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration

Frontiers in Molecular Neuroscience

Volumn 7, Issue JAN, 2015, Pages 1-20

  Figueiredo Pereira, Maria E ^a   Rockwell, Patricia ^a   Schmidt Glenewinkel, Thomas ^a   Serrano, Peter ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

J2 prostaglandins; Mitochondria; Neurodegeneration; Neuroinflammation; UPP

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; ARACHIDONIC ACID; CALCIUM; CELL NUCLEUS RECEPTOR; CYCLIC AMP; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DYNAMIN RELATED PROTEIN 1; G PROTEIN COUPLED RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 8; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOLIPASE A2; PHOSPHOLIPASE D2; PROSTAGLANDIN J2; PROSTAGLANDIN TRANSPORTER; PROSTANOID; PROTEASOME; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN INJURY; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATION; DEMYELINATION; GLOBOID CELL LEUKODYSTROPHY; HIV ASSOCIATED DEMENTIA; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INTRACELLULAR SIGNALING; MICHAEL ADDITION; MITOCHONDRION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRION DISEASE; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; TRAUMATIC BRAIN INJURY;

EID: 84920983279     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2014.00104     Document Type: Review

References (237)

1. Abdel-Halim, M. S., Hamberg, M., Sjoquist, B., and Anggard, E. (1977). Identification of prostaglandin D2 as a major prostaglandin in homogenates of rat brain. Prostaglandins 14, 633-643. doi: 10.1016/0090-6980(77)90190-3
2. Ahmad, A. S., Ahmad, M., Maruyama, T., Narumiya, S., and Dore, S. (2010). Prostaglandin D2 DP1 receptor is beneficial in ischemic stroke and in acute exicitotoxicity in young and old mice. Age (Dordr.) 32, 271-282. doi: 10.1007/s11357-010-9135-y
3. Aid, S., and Bosetti, F. (2011). Targeting cyclooxygenases-1 and -2 in neuroinflammation: therapeutic implications.Biochimie 93, 46-51. doi: 10.1016/j.biochi.2010.09.009
4. Aiken, C. T., Kaake, R. M., Wang, X., and Huang, L. (2011). Oxidative stress-mediated regulation of proteasome complexes. Mol. Cell Proteomics 10, R110. doi: 10.1074/mcp.M110.006924
5. Aoki, T., and Narumiya, S. (2012). Prostaglandins and chronic inflammation. Trends Pharmacol. Sci. 33, 304-311. doi: 10.1016/j.tips.2012.02.004
6. Arbuzova, A., Schmitz, A. A., and Vergeres, G. (2002). Cross-talk unfolded: MARCKS proteins. Biochem. J. 362, 1-12. doi: 10.1042/0264-6021:3620001
7. Arnaud, L. T., Myeku, N., and Figueiredo-Pereira, M. E. (2009). Proteasome-caspase-cathepsin sequence leading to tau pathology induced by prostaglandin J2 in neuronal cells. J. Neurochem. 110, 328-342. doi: 10.1111/j.1471-4159.2009.06142.x
8. Astudillo, A. M., Balgoma, D., Balboa, M. A., and Balsinde, J. (2012). Dynamics of arachidonic acid mobilization by inflammatory cells. Biochim. Biophys. Acta 1821, 249-256. doi: 10.1016/j.bbalip.2011.11.006
9. Atlasz, T., Szabadfi, K., Kiss, P., Tamas, A., Toth, G., Reglodi, D., et al. (2010). Evaluation of the protective effects of PACAP with cell-specific markers in ischemia-induced retinal degeneration. Brain Res. Bull. 81, 497-504. doi: 10.1016/j.brainresbull.2009.09.004
10. Banati, R. B. (2002). Visualising microglial activation in vivo. Glia 40, 206-217. doi: 10.1002/glia.10144
11. Banu, S. K., Arosh, J. A., Chapdelaine, P., and Fortier, M. A. (2003). Molecular cloning and spatio-temporal expression of the prostaglandin transporter: a basis for the action of prostaglandins in the bovine reproductive system. Proc. Natl. Acad. Sci. U.S.A. 100, 11747-11752. doi: 10.1073/pnas.1833330100
12. Bartels, A. L., and Leenders, K. L. (2010). Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration. Curr. Neuropharmacol. 8, 62-68. doi: 10.2174/157015910790909485
13. Becker, C., Jick, S. S., and Meier, C. R. (2010). Risk of stroke in patients with idiopathic Parkinson disease.Parkinsonism. Relat. Disord. 16, 31-35. doi: 10.1016/j.parkreldis.2009.06.005
14. Bellingham, S. A., Guo, B. B., Coleman, B. M., and Hill, A. F. (2012). Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front. Physiol. 3:124. doi: 10.3389/fphys.2012.00124
15. Bernardo, A., Ajmone-Cat, M. A., Levi, G., and Minghetti, L. (2003). 15-Deoxy-delta12,14-prostaglandin J2 regulates the functional state and the survival of microglial cells through multiple molecular mechanisms. J. Neurochem. 87, 742-751. doi: 10.1046/j.1471-4159.2003.02045.x
16. Bhattacharya, M., Peri, K. G., Almazan, G., Ribeiro-da-Silva, A., Shichi, H., Durocher, Y., et al. (1998). Nuclear localization of prostaglandin E2 receptors. Proc. Natl. Acad. Sci. U.S.A. 95, 15792-15797. doi: 10.1073/pnas.95.26.15792
17. Bi, W., Jing, X., Zhu, L., Liang, Y., Liu, J., Yang, L., et al. (2012). Inhibition of 26S protease regulatory subunit 7 (MSS1) suppresses neuroinflammation. PLoS ONE 7:e36142. doi: 10.1371/journal.pone.0036142
18. Bi, W., Zhu, L., Zeng, Z., Jing, X., Liang, Y., Guo, L., et al. (2014). Investigations into the role of 26S proteasome non-ATPase regulatory subunit 13 in neuroinflammation. Neuroimmunomodulation 21, 331-337. doi: 10.1159/000357811
19. Bingol, B., Tea, J. S., Phu, L., Reichelt, M., Bakalarski, C. E., Song, Q., et al. (2014). The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature 510, 370-375. doi: 10.1038/nature13418
20. Blanco, M., Moro, M. A., Davalos, A., Leira, R., Castellanos, M., Serena, J., et al. (2005). Increased plasma levels of 15-deoxyDelta prostaglandin J2 are associated with good outcome in acute atherothrombotic ischemic stroke.Stroke 36, 1189-1194. doi: 10.1161/01.STR.0000166054.55993.e5
21. Bosetti, F. (2007). Arachidonic acid metabolism in brain physiology and pathology: lessons from genetically altered mouse models. J. Neurochem. 102, 577-586. doi: 10.1111/j.1471-4159.2007.04558.x
22. Calabrese, B., and Halpain, S. (2005). Essential role for the PKC target MARCKS in maintaining dendritic spine morphology. Neuron 48, 77-90. doi: 10.1016/j.neuron.2005.08.027
23. Caldeira, M. V., Salazar, I. L., Curcio, M., Canzoniero, L. M., and Duarte, C. B. (2014). Role of the ubiquitin-proteasome system in brain ischemia: friend or foe? Prog. Neurobiol. 112, 50-69. doi: 10.1016/j.pneurobio.2013.10.003
24. Castagnet, P. I., Golovko, M. Y., Barcelo-Coblijn, G. C., Nussbaum, R. L., and Murphy, E. J. (2005). Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-ablated mice. J. Neurochem. 94, 839-849. doi: 10.1111/j.1471-4159.2005.03247.x
25. Ceaser, E. K., Moellering, D. R., Shiva, S., Ramachandran, A., Landar, A., Venkartraman, A., et al. (2004). Mechanisms of signal transduction mediated by oxidized lipids: the role of the electrophile-responsive proteome.Biochem. Soc. Trans. 32, 151-155. doi: 10.1042/BST0320151
26. Cernuda-Morollon, E., Pineda-Molina, E., Canada, F. J., and Perez-Sala, D. (2001). 15-Deoxy-Delta 12,14-prostaglandin J2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit. J. Biol. Chem. 276, 35530-35536. doi: 10.1074/jbc.M104518200
27. Chan, B. S., Endo, S., Kanai, N., and Schuster, V. L. (2002). Identification of lactate as a driving force for prostanoid transport by prostaglandin transporter PGT. Am. J. Physiol. Renal. Physiol. 282, F1097-F1102. doi: 10.1152/ajprenal.00151.2001
28. Chaudhuri, A. (2013). Multiple sclerosis is primarily a neurodegenerative disease. J. Neural Transm. 120, 1463-1466. doi: 10.1007/s00702-013-1080-3
29. Chi, Y., Khersonsky, S. M., Chang, Y. T., and Schuster, V. L. (2006). Identification of a new class of prostaglandin transporter inhibitors and characterization of their biological effects on prostaglandin E2 transport. J. Pharmacol. Exp. Ther. 316, 1346-1350. doi: 10.1124/jpet.105.091975
30. Chi, Y., Min, J., Jasmin, J. F., Lisanti, M. P., Chang, Y. T., and Schuster, V. L. (2011). Development of a high-affinity inhibitor of the prostaglandin transporter. J. Pharmacol. Exp. Ther. 339, 633-641. doi: 10.1124/jpet.111.181354
31. Chi, Y., and Schuster, V. L. (2010). The prostaglandin transporter PGT transports PGH(2). Biochem. Biophys. Res. Commun. 395, 168-172. doi: 10.1016/j.bbrc.2010.03.108
32. Chi, Y., Suadicani, S., and Schuster, V. L. (2014). Regulation of prostaglandin EP1 and EP4 receptor signaling by carrier-meditaed ligand reuptake. Pharma Res. Per. 2:e00051. doi: 10.1002/prp2.51
33. Chivet, M., Javalet, C., Hemming, F., Pernet-Gallay, K., Laulagnier, K., Fraboulet, S., et al. (2013). Exosomes as a novel way of interneuronal communication. Biochem. Soc. Trans. 41, 241-244. doi: 10.1042/BST20120266
34. Choi, J., Levey, A. I., Weintraub, S. T., Rees, H. D., Gearing, M., Chin, L. S., et al. (2004). Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 279, 13256-13264. doi: 10.1074/jbc.M314124200
35. Choi, K., Zhuang, H., Crain, B., and Dore, S. (2008). Expression and localization of prostaglandin transporter in Alzheimer disease brains and age-matched controls. J. Neuroimmunol. 195, 81-87. doi: 10.1016/j.jneuroim.2008.01.014
36. Choi, S. H., Aid, S., and Bosetti, F. (2009). The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol. Sci. 30, 174-181. doi: 10.1016/j.tips.2009.01.002
37. Clague, M. J., Barsukov, I., Coulson, J. M., Liu, H., Rigden, D. J., and Urbe, S. (2013). Deubiquitylases from genes to organism. Physiol. Rev. 93, 1289-1315. doi: 10.1152/physrev.00002.2013
38. Clay, C. E., Namen, A. M., Atsumi, G., Willingham, M. C., High, K. P., Kute, T. E., et al. (1999). Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 20, 1905-1911. doi: 10.1093/carcin/20.10.1905
39. Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., and Landreth, G. E. (2000). Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 20, 558-567.
40. Consilvio, C., Vincent, A. M., and Feldman, E. L. (2004). Neuroinflammation, COX-2, and ALS-a dual role? Exp. Neurol. 187, 1-10. doi: 10.1016/j.expneurol.2003.12.009
41. Crosas, B. (2014). Deubiquitinating enzyme inhibitors and their potential in cancer therapy. Curr. Cancer Drug Targets 14, 506-516. doi: 10.2174/1568009614666140725090620
42. Cudaback, E., Jorstad, N. L., Yang, Y., Montine, T. J., and Keene, C. D. (2014). Therapeutic implications of the prostaglandin pathway in Alzheimer's disease. Biochem. Pharmacol. 88, 565-572. doi: 10.1016/j.bcp.2013.12.014
43. de Boer, A. S., Koszka, K., Kiskinis, E., Suzuki, N., Davis-Dusenbery, B. N., and Eggan, K. (2014). Genetic validation of a therapeutic target in a mouse model of ALS. Sci. Transl. Med. 6, 248ra104. doi: 10.1126/scitranslmed.3009351
44. de Calignon, A., Fox, L. M., Pitstick, R., Carlson, G. A., Bacskai, B. J., Spires-Jones, T. L., et al. (2010). Caspase activation precedes and leads to tangles. Nature 464, 1201-1204. doi: 10.1038/nature08890
45. Dejda, A., Seaborn, T., Bourgault, S., Touzani, O., Fournier, A., Vaudry, H., et al. (2011). PACAP and a novel stable analog protect rat brain from ischemia: insight into the mechanisms of action. Peptides 32, 1207-1216. doi: 10.1016/j.peptides.2011.04.003
46. Diab, A., Deng, C., Smith, J. D., Hussain, R. Z., Phanavanh, B., Lovett-Racke, A. E., et al. (2002). Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168, 2508-2515. doi: 10.4049/jimmunol.168.5.2508
47. Diers, A. R., Higdon, A. N., Ricart, K. C., Johnson, M. S., Agarwal, A., Kalyanaraman, B., et al. (2010). Mitochondrial targeting of the electrophilic lipid 15-deoxy-Delta12,14-prostaglandin J2 increases apoptotic efficacy via redox cell signalling mechanisms. Biochem. J. 426, 31-41. doi: 10.1042/BJ20091293
48. Di Giorgio, F. P., Boulting, G. L., Bobrowicz, S., and Eggan, K. C. (2008). Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 3, 637-648. doi: 10.1016/j.stem.2008.09.017
49. Duchen, L. W., Eicher, E. M., Jacobs, J. M., Scaravilli, F., and Teixeira, F. (1980). Hereditary leucodystrophy in the mouse: the new mutant twitcher. Brain 103, 695-710. doi: 10.1093/brain/103.3.695
50. Edelmann, M. J., Nicholson, B., and Kessler, B. M. (2011). Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Expert Rev. Mol. Med. 13, e35. doi: 10.1017/S1462399411002031
51. Eletr, Z. M., and Wilkinson, K. D. (2014). Regulation of proteolysis by human deubiquitinating enzymes. Biochim. Biophys. Acta 1843, 114-128. doi: 10.1016/j.bbamcr.2013.06.027
52. Eucker, J., Bangeroth, K., Zavrski, I., Krebbel, H., Zang, C., Heider, U., et al. (2004). Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma. Anticancer Drugs 15, 955-960. doi: 10.1097/00001813-200411000-00004
53. Exner, N., Lutz, A. K., Haass, C., and Winklhofer, K. F. (2012). Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 31, 3038-3062. doi: 10.1038/emboj.2012.170
54. Feng, Z., Li, D., Fung, P. C., Pei, Z., Ramsden, D. B., and Ho, S. L. (2003). COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice. Neuroreport 14, 1927-1929. doi: 10.1097/00001756-200310270-00009
55. Funk, C. D. (2001). Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294, 1871-1875. doi: 10.1126/science.294.5548.1871
56. Gamblin, T. C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A. L., et al. (2003). Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 100, 10032-10037. doi: 10.1073/pnas.1630428100
57. Gilroy, D. W. (2010). Eicosanoids and the endogenous control of acute inflammatory resolution. Int. J. Biochem. Cell Biol. 42, 524-528. doi: 10.1016/j.biocel.2009.12.013
58. Giri, S., Rattan, R., Singh, A. K., and Singh, I. (2004). The 15-deoxy-delta12,14-prostaglandin J2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-kappaB-p300 pathway independent of peroxisome proliferator-activated receptor gamma. J. Immunol. 173, 5196-5208. doi: 10.4049/jimmunol.173.8.5196
59. Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., and Gage, F. H. (2010). Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934. doi: 10.1016/j.cell.2010.02.016
60. Golovko, M. Y., and Murphy, E. J. (2008). Brain prostaglandin formation is increased by alpha-synuclein gene-ablation during global ischemia. Neurosci. Lett. 432, 243-247. doi: 10.1016/j.neulet.2007.12.031
61. Golovko, M. Y., Rosenberger, T. A., Faergeman, N. J., Feddersen, S., Cole, N. B., Pribill, I., et al. (2006). Acyl-CoA synthetase activity links wild-type but not mutant alpha-synuclein to brain arachidonate metabolism.Biochemistry 45, 6956-6966. doi: 10.1021/bi0600289
62. Gutierrez, J., Ballinger, S. W., Darley-Usmar, V. M., and Landar, A. (2006). Free radicals, mitochondria, and oxidized lipids: the emerging role in signal transduction in vascular cells. Circ. Res. 99, 924-932. doi: 10.1161/01.RES.0000248212.86638.e9
63. Haas, A. L., Warms, J. V., Hershko, A., and Rose, I. A. (1982). Ubiquitin-activating enzyme. Mechanism and role in protein-ubiquitin conjugation. J. Biol. Chem. 257, 2543-2548.
64. Haddad, A., Flint-Ashtamker, G., Minzel, W., Sood, R., Rimon, G., and Barki-Harrington, L. (2012). Prostaglandin EP1 receptor down-regulates expression of cyclooxygenase-2 by facilitating its proteasomal degradation. J. Biol. Chem. 287, 17214-17223. doi: 10.1074/jbc.M111.304220
65. Hardy, K. D., Cox, B. E., Milne, G. L., Yin, H., and Roberts, L. J. (2011). Nonenzymatic free radical-catalyzed generation of 15-deoxy-Delta(12,14)-prostaglandin J(2)-like compounds (deoxy-J(2)-isoprostanes) in vivo. J. Lipid Res. 52, 113-124. doi: 10.1194/jlr.M010264
66. Harrington, M. G., Fonteh, A. N., Biringer, R. G., AF, R. H., and Cowan, R. P. (2006). Prostaglandin D synthase isoforms from cerebrospinal fluid vary with brain pathology. Dis. Markers 22, 73-81. doi: 10.1155/2006/241817
67. Harris, S. G., Padilla, J., Koumas, L., Ray, D., and Phipps, R. P. (2002). Prostaglandins as modulators of immunity.Trends Immunol. 23, 144-150. doi: 10.1016/S1471-4906(01)02154-8
68. Haskew-Layton, R. E., Payappilly, J. B., Xu, H., Bennett, S. A., and Ratan, R. R. (2013). 15-Deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) protects neurons from oxidative death via an Nrf2 astrocyte-specific mechanism independent of PPARgamma. J. Neurochem. 124, 536-547. doi: 10.1111/jnc.12107
69. Hata, A. N., and Breyer, R. M. (2004). Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 103, 147-166. doi: 10.1016/j.pharmthera.2004.06.003
70. Herrup, K. (2010). Reimagining Alzheimer's disease-an age-based hypothesis. J. Neurosci. 30, 16755-16762. doi: 10.1523/JNEUROSCI.4521-10.2010
71. Hertting, G., and Seregi, A. (1989). Formation and function of eicosanoids in the central nervous system. Ann. N. Y. Acad. Sci. 559, 84-99. doi: 10.1111/j.1749-6632.1989.tb22600.x
72. Hickey, R. W., Adelson, P. D., Johnnides, M. J., Davis, D. S., Yu, Z., Rose, M. E., et al. (2007). Cyclooxygenase-2 activity following traumatic brain injury in the developing rat. Pediatr. Res. 62, 271-276. doi: 10.1203/PDR.0b013e3180db2902
73. Higdon, A., Diers, A. R., Oh, J. Y., Landar, A., and Darley-Usmar, V. M. (2012a). Cell signalling by reactive lipid species: new concepts and molecular mechanisms. Biochem. J. 442, 453-464.
74. Higdon, A. N., Landar, A., Barnes, S., and Darley-Usmar, V. M. (2012b). The electrophile responsive proteome: integrating proteomics and lipidomics with cellular function. Antioxid. Redox. Signal. 17, 1580-1589. doi: 10.1089/ars.2012.4523
75. Hirata, Y., Hayashi, H., Ito, S., Kikawa, Y., Ishibashi, M., Sudo, M., et al. (1988). Occurrence of 9-deoxy-delta 9,delta 12-13,14-dihydroprostaglandin D2 in human urine. J. Biol. Chem. 263, 16619-16625.
76. Homem de Bittencourt, P. I. Jr., Lagranha, D. J., Maslinkiewicz, A., Senna, S. M., Tavares, A. M., Baldissera, L. P., et al. (2007). LipoCardium: endothelium-directed cyclopentenone prostaglandin-based liposome formulation that completely reverses atherosclerotic lesions. Atherosclerosis 193, 245-258. doi: 10.1016/j.atherosclerosis.2006.08.049
77. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., et al. (1996). Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice [see comments]. Science 274, 99-102. doi: 10.1126/science.274.5284.99
78. Huang, Q., Wang, H., Perry, S. W., and Figueiredo-Pereira, M. E. (2013). Negative regulation of 26S proteasome stability via calpain-mediated cleavage of Rpn10 subunit upon mitochondrial dysfunction in neurons. J. Biol. Chem. 288, 12161-12174. doi: 10.1074/jbc.M113.464552
79. Iadecola, C., and Gorelick, P. B. (2005). The Janus face of cyclooxygenase-2 in ischemic stroke: shifting toward downstream targets. Stroke 36, 182-185. doi: 10.1161/01.STR.0000153797.33611.d8
80. Ishii, T., Sakurai, T., Usami, H., and Uchida, K. (2005). Oxidative modification of proteasome: identification of an oxidation-sensitive subunit in 26 s proteasome. Biochemistry 44, 13893-13901. doi: 10.1021/bi051336u
81. Ishii, T., and Uchida, K. (2004). Induction of reversible cysteine-targeted protein oxidation by an endogenous electrophile 15-deoxy-delta12,14-prostaglandin J2. Chem. Res. Toxicol. 17, 1313-1322. doi: 10.1021/tx049860+
82. Itoh, K., Mochizuki, M., Ishii, Y., Ishii, T., Shibata, T., Kawamoto, Y., et al. (2004). Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)-prostaglandin j(2). Mol. Cell Biol. 24, 36-45. doi: 10.1128/MCB.24.1.36-45.2004
83. Itoh, S., Lu, R., Bao, Y., Morrow, J. D., Roberts, L. J., and Schuster, V. L. (1996). Structural determinants of substrates for the prostaglandin transporter PGT. Mol. Pharmacol. 50, 738-742.
84. Iwamoto, N., Kobayashi, K., and Kosaka, K. (1989). The formation of prostaglandins in the postmortem cerebral cortex of Alzheimer-type dementia patients. J. Neurol. 236, 80-84. doi: 10.1007/BF00314401
85. Jones, R. L., Giembycz, M. A., and Woodward, D. F. (2009). Prostanoid receptor antagonists: development strategies and therapeutic applications. Br. J. Pharmacol. 158, 104-145. doi: 10.1111/j.1476-5381.2009.00317.x
86. Kanai, N., Lu, R., Satriano, J. A., Bao, Y., Wolkoff, A. W., and Schuster, V. L. (1995). Identification and characterization of a prostaglandin transporter. Science 268, 866-869. doi: 10.1126/science.7754369
87. Kanaoka, Y., and Urade, Y. (2003). Hematopoietic prostaglandin D synthase. Prostaglandins Leukot. Essent. Fatty Acids 69, 163-167. doi: 10.1016/S0952-3278(03)00077-2
88. Kanekiyo, T., Ban, T., Aritake, K., Huang, Z. L., Qu, W. M., Okazaki, I., et al. (2007). Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid. Proc. Natl. Acad. Sci. U.S.A. 104, 6412-6417. doi: 10.1073/pnas.0701585104
89. Kapadia, R., Yi, J. H., and Vemuganti, R. (2008). Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front. Biosci. 13:1813-1826. doi: 10.2741/2802
90. Kaspar, J. W., Niture, S. K., and Jaiswal, A. K. (2009). Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic. Biol. Med. 47, 1304-1309. doi: 10.1016/j.freeradbiomed.2009.07.035
91. Katura, T., Moriya, T., and Nakahata, N. (2010). 15-Deoxy-delta 12,14-prostaglandin J2 biphasically regulates the proliferation of mouse hippocampal neural progenitor cells by modulating the redox state. Mol. Pharmacol. 77, 601-611. doi: 10.1124/mol.109.061010
92. Kiaei, M. (2008). Peroxisome proliferator-activated receptor-gamma in amyotrophic lateral sclerosis and Huntington's disease. PPAR. Res. 2008, 418765. doi: 10.1155/2008/418765
93. Kim, E. H., Na, H. K., Kim, D. H., Park, S. A., Kim, H. N., Song, N. Y., et al. (2008). 15-Deoxy-Delta12,14-prostaglandin J2 induces COX-2 expression through Akt-driven AP-1 activation in human breast cancer cells: a potential role of ROS. Carcinogenesis 29, 688-695. doi: 10.1093/carcin/bgm299
94. Kitz, K., Windischhofer, W., Leis, H. J., Huber, E., Kollroser, M., and Malle, E. (2011). 15-Deoxy-Delta12,14-prostaglandin J2 induces Cox-2 expression in human osteosarcoma cells through MAPK and EGFR activation involving reactive oxygen species. Free Radic. Biol. Med. 50, 854-865. doi: 10.1016/j.freeradbiomed.2010.12.039
95. Klegeris, A., McGeer, E. G., and McGeer, P. L. (2007). Therapeutic approaches to inflammation in neurodegenerative disease. Curr. Opin. Neurol. 20, 351-357. doi: 10.1097/WCO.0b013e3280adc943
96. Klivenyi, P., Gardian, G., Calingasan, N. Y., Yang, L., and Beal, M. F. (2003). Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Mol. Neurosci. 21, 191-198. doi: 10.1385/JMN:21:3:191
97. Kobayashi, T., Yamanaka, T., Jacobs, J. M., Teixeira, F., and Suzuki, K. (1980). The Twitcher mouse: an enzymatically authentic model of human globoid cell leukodystrophy (Krabbe disease). Brain Res. 202, 479-483. doi: 10.1016/0006-8993(80)90159-6
98. Koharudin, L. M., Liu, H., Di, M. R., Kodali, R. B., Graham, S. H., and Gronenborn, A. M. (2010). Cyclopentenone prostaglandin-induced unfolding and aggregation of the Parkinson disease-associated UCH-L1. Proc. Natl. Acad. Sci. U.S.A. 107, 6835-6840. doi: 10.1073/pnas.1002295107
99. Kondo, M., Oya-Ito, T., Kumagai, T., Osawa, T., and Uchida, K. (2001). Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress. J. Biol. Chem. 276, 12076-12083. doi: 10.1074/jbc.M009630200
100. Kondo, M., Shibata, T., Kumagai, T., Osawa, T., Shibata, N., Kobayashi, M., et al. (2002). 15-Deoxy-Delta(12,14)-prostaglandin J(2): the endogenous electrophile that induces neuronal apoptosis. Proc. Natl. Acad. Sci. U.S.A. 99, 7367-7372. doi: 10.1073/pnas.112212599
101. Kulkarni, S. K., Jain, N. K., and Singh, A. (2000). Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors. Methods Find. Exp. Clin. Pharmacol. 22, 291-298. doi: 10.1358/mf.2000.22.5.796648
102. Kunz, T., Marklund, N., Hillered, L., and Oliw, E. H. (2002). Cyclooxygenase-2, prostaglandin synthases, and prostaglandin H2 metabolism in traumatic brain injury in the rat. J. Neurotrauma 19, 1051-1064. doi: 10.1089/089771502760341965
103. Lachenal, G., Pernet-Gallay, K., Chivet, M., Hemming, F. J., Belly, A., Bodon, G., et al. (2011). Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity. Mol. Cell Neurosci. 46, 409-418. doi: 10.1016/j.mcn.2010.11.004
104. Lee, B. H., Lee, M. J., Park, S., Oh, D. C., Elsasser, S., Chen, P. C., et al. (2010). Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467, 179-184. doi: 10.1038/nature09299
105. Lee, D. R., Kwon, C. H., Park, J. Y., Kim, Y. K., and Woo, J. S. (2009). 15-Deoxy-Delta(12,14)-prostaglandin J(2) induces mitochondrial-dependent apoptosis through inhibition of PKA/NF-kappaB in renal proximal epithelial cells. Toxicology 258, 17-24. doi: 10.1016/j.tox.2009.01.001
106. Lee, S., Jang, E., Kim, J. H., Kim, J. H., Lee, W. H., and Suk, K. (2012). Lipocalin-type prostaglandin D2 synthase protein regulates glial cell migration and morphology through myristoylated alanine-rich C-kinase substrate: prostaglandin D2-independent effects. J. Biol. Chem. 287, 9414-9428. doi: 10.1074/jbc.M111.330662
107. Legg, K. (2011). Neurodegenerative diseases: an alternative path to reduce neuroinflammation. Nat. Rev. Drug Discov. 10:901. doi: 10.1038/nrd3607
108. Li, Z., Jansen, M., Ogburn, K., Salvatierra, L., Hunter, L., Mathew, S., et al. (2004a). Neurotoxic prostaglandin J2 enhances cyclooxygenase-2 expression in neuronal cells through the p38MAPK pathway: a death wish? J. Neurosci. Res. 78, 824-836. doi: 10.1002/jnr.20346
109. Li, Z., Melandri, F., Berdo, I., Jansen, M., Hunter, L., Wright, S., et al. (2004b). Delta12-Prostaglandin J2 inhibits the ubiquitin hydrolase UCH-L1 and elicits ubiquitin-protein aggregation without proteasome inhibition. Biochem. Biophys. Res. Commun. 319, 1171-1180. doi: 10.1016/j.bbrc.2004.05.098
110. Liang, X., Wu, L., Hand, T., and Andreasson, K. (2005). Prostaglandin D2 mediates neuronal protection via the DP1 receptor. J. Neurochem. 92, 477-486. doi: 10.1111/j.1471-4159.2004.02870.x
111. Liang, X., Wu, L., Wang, Q., Hand, T., Bilak, M., McCullough, L., et al. (2007). Function of COX-2 and prostaglandins in neurological disease. J. Mol. Neurosci. 33, 94-99. doi: 10.1007/s12031-007-0058-8
112. Lima, I. V., Bastos, L. F., Limborco-Filho, M., Fiebich, B. L., and de Oliveira, A. C. (2012). Role of prostaglandins in neuroinflammatory and neurodegenerative diseases. Mediators Inflamm. 2012:946813. doi: 10.1155/2012/946813
113. Lin, M. T., and Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases.Nature 443, 787-795. doi: 10.1038/nature05292
114. Liu, B., Gao, H. M., and Hong, J. S. (2003). Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ. Health Perspect. 111, 1065-1073. doi: 10.1289/ehp.6361
115. Liu, B., and Hong, J. S. (2003). Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 304, 1-7. doi: 10.1124/jpet.102.035048
116. Liu, C. W., Li, X., Thompson, D., Wooding, K., Chang, T. L., Tang, Z., et al. (2006). ATP binding and ATP hydrolysis play distinct roles in the function of 26S proteasome. Mol. Cell 24, 39-50. doi: 10.1016/j.molcel.2006.08.025
117. Liu, H., Li, W., Ahmad, M., Miller, T. M., Rose, M. E., Poloyac, S. M., et al. (2011). Modification of ubiquitin-C-terminal hydrolase-L1 by cyclopentenone prostaglandins exacerbates hypoxic injury. Neurobiol. Dis. 41, 318-328. doi: 10.1016/j.nbd.2010.09.020
118. Liu, H., Li, W., Ahmad, M., Rose, M. E., Miller, T. M., Yu, M., et al. (2013a). Increased generation of cyclopentenone prostaglandins after brain ischemia and their role in aggregation of ubiquitinated proteins in neurons. Neurotox. Res. 24, 191-204. doi: 10.1007/s12640-013-9377-4
119. Liu, H., Li, W., Rose, M. E., Pascoe, J. L., Miller, T. M., Ahmad, M., et al. (2013b). Prostaglandin D toxicity in primary neurons is mediated through its bioactive cyclopentenone metabolites. Neurotoxicology 39C, 35-44. doi: 10.1016/j.neuro.2013.08.001
120. Liu, H., Rose, M. E., Miller, T. M., Li, W., Shinde, S. N., Pickrell, A. M., et al. (2013c). COX2-derived primary and cyclopentenone prostaglandins are increased after asphyxial cardiac arrest. Brain Res. 1519, 71-77. doi: 10.1016/j.brainres.2013.04.029
121. Livnat-Levanon, N., and Glickman, M. H. (2011). Ubiquitin-proteasome system and mitochondria - reciprocity.Biochim. Biophys. Acta 1809, 80-87. doi: 10.1016/j.bbagrm.2010.07.005
122. Lu, R., Kanai, N., Bao, Y., and Schuster, V. L. (1996). Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J. Clin. Invest. 98, 1142-1149. doi: 10.1172/JCI118897
123. Lucin, K. M., and Wyss-Coray, T. (2009). Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 64, 110-122. doi: 10.1016/j.neuron.2009.08.039
124. Mao, S. S., Hua, R., Zhao, X. P., Qin, X., Sun, Z. Q., Zhang, Y., et al. (2012). Exogenous administration of PACAP alleviates traumatic brain injury in rats through a mechanism involving the TLR4/MyD88/NF-kappaB pathway. J. Neurotrauma 29, 1941-1959. doi: 10.1089/neu.2011.2244
125. Marcone, S., and Fitzgerald, D. J. (2013). Proteomic identification of the candidate target proteins of 15-deoxy-delta12,14-prostaglandin J2. Proteomics 13, 2135-2139. doi: 10.1002/pmic.201200289
126. Martinez, B., Perez-Castillo, A., and Santos, A. (2005). The mitochondrial respiratory complex I is a target for 15-deoxy-delta12,14-prostaglandin J2 action. J. Lipid Res. 46, 736-743. doi: 10.1194/jlr.M400392-JLR200
127. Mbonye, U. R., Wada, M., Rieke, C. J., Tang, H. Y., DeWitt, D. L., and Smith, W. L. (2006). The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system. J. Biol. Chem. 281, 35770-35778. doi: 10.1074/jbc.M608281200
128. Mbonye, U. R., Yuan, C., Harris, C. E., Sidhu, R. S., Song, I., Arakawa, T., et al. (2008). Two distinct pathways for cyclooxygenase-2 protein degradation. J. Biol. Chem. doi: 10.1074/jbc.M710137200
129. Meade, E. A., McIntyre, T. M., Zimmerman, G. A., and Prescott, S. M. (1999). Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J. Biol. Chem. 274, 8328-8334. doi: 10.1074/jbc.274.12.8328
130. Metcalfe, M. J., Huang, Q., and Figueiredo-Pereira, M. E. (2012). Coordination between proteasome impairment and caspase activation leading to TAU pathology: neuroprotection by cAMP. Cell Death Dis. 3, e326. doi: 10.1038/cddis.2012.70
131. Metzger, M. B., Pruneda, J. N., Klevit, R. E., and Weissman, A. M. (2014). RING-type E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination. Biochim. Biophys. Acta 1843, 47-60. doi: 10.1016/j.bbamcr.2013.05.026
132. Mishra, N., Kar, R., Singha, P. K., Venkatachalam, M. A., McEwen, D. G., and Saikumar, P. (2010). Inhibition of mitochondrial division through covalent modification of Drp1 protein by 15 deoxy-Delta(12,14)-prostaglandin J2.Biochem. Biophys. Res. Commun. 395, 17-24. doi: 10.1016/j.bbrc.2010.03.093
133. Mohri, I., Kadoyama, K., Kanekiyo, T., Sato, Y., Kagitani-Shimono, K., Saito, Y., et al. (2007). Hematopoietic prostaglandin D synthase and DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease. J. Neuropathol. Exp. Neurol. 66, 469-480. doi: 10.1097/01.jnen.0000240472.43038.27
134. Mohri, I., Taniike, M., Taniguchi, H., Kanekiyo, T., Aritake, K., Inui, T., et al. (2006). Prostaglandin D2-mediated microglia/astrocyte interaction enhances astrogliosis and demyelination in twitcher. J. Neurosci. 26, 4383-4393. doi: 10.1523/JNEUROSCI.4531-05.2006
135. Monneret, G., Li, H., Vasilescu, J., Rokach, J., and Powell, W. S. (2002). 15-Deoxy-delta 12,14-prostaglandins D2 and J2 are potent activators of human eosinophils. J. Immunol. 168, 3563-3569. doi: 10.4049/jimmunol.168.7.3563
136. Moody, T. W., Ito, T., Osefo, N., and Jensen, R. T. (2011). VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies. Curr. Opin. Endocrinol. Diabetes Obes. 18, 61-67. doi: 10.1097/MED.0b013e328342568a
137. Moos, P. J., Edes, K., Cassidy, P., Massuda, E., and Fitzpatrick, F. A. (2003). Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J. Biol. Chem. 278, 745-750. doi: 10.1074/jbc.M211134200
138. Morel, L., Regan, M., Higashimori, H., Ng, S. K., Esau, C., Vidensky, S., et al. (2013). Neuronal exosomal miRNA-dependent translational regulation of astroglial glutamate transporter GLT1. J. Biol. Chem. 288, 7105-7116. doi: 10.1074/jbc.M112.410944
139. Mosher, K. I., and Wyss-Coray, T. (2014). Microglial dysfunction in brain aging and Alzheimer's disease. Biochem. Pharmacol. 88, 594-604. doi: 10.1016/j.bcp.2014.01.008
140. Mrak, R. E., and Landreth, G. E. (2004). PPARgamma, neuroinflammation, and disease. J. Neuroinflammation 1:5. doi: 10.1186/1742-2094-1-5
141. Mullally, J. E., Moos, P. J., Edes, K., and Fitzpatrick, F. A. (2001). Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. J. Biol. Chem. 276, 30366-30373. doi: 10.1074/jbc.M102198200
142. Murray, J. J., Tonnel, A. B., Brash, A. R., Roberts, L. J., Gosset, P., Workman, R., et al. (1986). Release of prostaglandin D2 into human airways during acute antigen challenge. N. Engl. J. Med. 315, 800-804. doi: 10.1056/NEJM198609253151304
143. Musiek, E. S., Milne, G. L., McLaughlin, B., and Morrow, J. D. (2005). Cyclopentenone eicosanoids as mediators of neurodegeneration: a pathogenic mechanism of oxidative stress-mediated and cyclooxygenase-mediated neurotoxicity. Brain Pathol. 15, 149-158. doi: 10.1111/j.1750-3639.2005.tb00512.x
144. Na, H. K., and Surh, Y. J. (2003). Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation. Biochem. Pharmacol. 66, 1381-1391. doi: 10.1016/S0006-2952(03)00488-X
145. Nakata, S., Yoshida, T., Shiraishi, T., Horinaka, M., Kouhara, J., Wakada, M., et al. (2006). 15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis. Mol. Cancer Ther. 5, 1827-1835. doi: 10.1158/1535-7163.MCT-06-0023
146. Narendra, D. P., and Youle, R. J. (2011). Targeting mitochondrial dysfunction: role for PINK1 and Parkin in mitochondrial quality control. Antioxid. Redox. Signal. 14, 1929-1938. doi: 10.1089/ars.2010.3799
147. Narumiya, S., Ogorochi, T., Nakao, K., and Hayaishi, O. (1982). Prostaglandin D2 in rat brain, spinal cord and pituitary: basal level and regional distribution. Life Sci. 31, 2093-2103. doi: 10.1016/0024-3205(82)90101-1
148. Ng, S. C., and Chan, F. K. (2010). NSAID-induced gastrointestinal and cardiovascular injury. Curr. Opin. Gastroenterol. 26, 611-617. doi: 10.1097/MOG.0b013e32833e91eb
149. Nicholls, D. G. (2008). Oxidative stress and energy crises in neuronal dysfunction. Ann. N. Y. Acad. Sci. 1147, 53-60. doi: 10.1196/annals.1427.002
150. Nolan, Y. M., Sullivan, A. M., and Toulouse, A. (2013). Parkinson's disease in the nuclear age of neuroinflammation.Trends Mol. Med. 19, 187-196. doi: 10.1016/j.molmed.2012.12.003
151. Nomura, D. K., Morrison, B. E., Blankman, J. L., Long, J. Z., Kinsey, S. G., Marcondes, M. C., et al. (2011). Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334, 809-813. doi: 10.1126/science.1209200
152. Nomura, T., Lu, R., Pucci, M. L., and Schuster, V. L. (2004). The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase. Mol. Pharmacol. 65, 973-978. doi: 10.1124/mol.65.4.973
153. Norman, P. (2014). Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin. Investig. Drugs 23, 55-66. doi: 10.1517/13543784.2013.839658
154. Oddo, S. (2008). The ubiquitin-proteasome system in Alzheimer's disease. J. Cell Mol. Med. 12, 363-373. doi: 10.1111/j.1582-4934.2008.00276.x
155. Oeste, C. L., and Perez-Sala, D. (2014). Modification of cysteine residues by cyclopentenone prostaglandins: interplay with redox regulation of protein function. Mass Spectrom. Rev. 33, 110-125. doi: 10.1002/mas.21383
156. Offenbacher, S., Odle, B. M., and Van Dyke, T. E. (1986). The use of crevicular fluid prostaglandin E2 levels as a predictor of periodontal attachment loss. J. Periodontal. Res. 21, 101-112. doi: 10.1111/j.1600-0765.1986.tb01443.x
157. Ogburn, K. D., and Figueiredo-Pereira, M. E. (2006). Cytoskeleton/endoplasmic reticulum collapse induced by prostaglandin J2 parallels centrosomal deposition of ubiquitinated protein aggregates. J. Biol. Chem. 281, 23274-23284. doi: 10.1074/jbc.M600635200
158. Ogorochi, T., Narumiya, S., Mizuno, N., Yamashita, K., Miyazaki, H., and Hayaishi, O. (1984). Regional distribution of prostaglandins D2, E2, and F2 alpha and related enzymes in postmortem human brain. J. Neurochem. 43, 71-82. doi: 10.1111/j.1471-4159.1984.tb06680.x
159. Ohkura, N., Shigetani, Y., Yoshiba, N., Yoshiba, K., and Okiji, T. (2014). Prostaglandin transporting protein-mediated prostaglandin E2 transport in lipopolysaccharide-inflamed rat dental pulp. J. Endod. 40, 1112-1117. doi: 10.1016/j.joen.2013.12.024
160. Ohtaki, H., Satoh, A., Nakamachi, T., Yofu, S., Dohi, K., Mori, H., et al. (2010). Regulation of oxidative stress by pituitary adenylate cyclase-activating polypeptide (PACAP) mediated by PACAP receptor. J. Mol. Neurosci. 42, 397-403. doi: 10.1007/s12031-010-9350-0
161. Oliva, J. L., Perez-Sala, D., Castrillo, A., Martinez, N., Canada, F. J., Bosca, L., et al. (2003). The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and activates H-Ras. Proc. Natl. Acad. Sci. U.S.A. 100, 4772-4777. doi: 10.1073/pnas.0735842100
162. Palumbo, S., and Bosetti, F. (2013). Alterations of brain eicosanoid synthetic pathway in multiple sclerosis and in animal models of demyelination: role of cyclooxygenase-2. Prostaglandins Leukot. Essent. Fatty Acids 89, 273-278. doi: 10.1016/j.plefa.2013.08.008
163. Paul, S. (2008). Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches. Bioessays 30, 1172-1184. doi: 10.1002/bies.20852
164. Paulitschke, V., Gruber, S., Hofstatter, E., Haudek-Prinz, V., Klepeisz, P., Schicher, N., et al. (2012). Proteome analysis identified the PPARgamma ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction. PLoS ONE 7:e46103. doi: 10.1371/journal.pone.0046103
165. Perez-Gonzalez, R., Gauthier, S. A., Kumar, A., and Levy, E. (2012). The exosome secretory pathway transports amyloid precursor protein carboxyl-terminal fragments from the cell into the brain extracellular space. J. Biol. Chem. 287, 43108-43115. doi: 10.1074/jbc.M112.404467
166. Pettipher, R., Hansel, T. T., and Armer, R. (2007). Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat. Rev. Drug Discov. 6, 313-325. doi: 10.1038/nrd2266
167. Pierre, S. R., Lemmens, M. A., and Figueiredo-Pereira, M. E. (2009). Subchronic infusion of the product of inflammation prostaglandin J2 models sporadic Parkinson's disease in mice. J. Neuroinflammation 6:18. doi: 10.1186/1742-2094-6-18
168. Pignatelli, M., Sanchez-Rodriguez, J., Santos, A., and Perez-Castillo, A. (2005). 15-Deoxy-{Delta}-12,14-prostaglandin J2 induces programmed cell death of breast cancer cells by a pleiotropic mechanism. Carcinogenesis26, 81-92. doi: 10.1093/carcin/bgh308
169. Piro, J. R., Benjamin, D. I., Duerr, J. M., Pi, Y., Gonzales, C., Wood, K. M., et al. (2012). A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep. 1, 617-623. doi: 10.1016/j.celrep.2012.05.001
170. Qi, L., Jacob, A., Wang, P., and Wu, R. (2010). Peroxisome proliferator activated receptor-gamma and traumatic brain injury. Int. J. Clin. Exp. Med. 3, 283-292.
171. Rainsford, K. D. (2007). Anti-inflammatory drugs in the 21st century. Subcell. Biochem. 42, 3-27. doi: 10.1007/1-4020-5688-5_1
172. Rajakariar, R., Hilliard, M., Lawrence, T., Trivedi, S., Colville-Nash, P., Bellingan, G., et al. (2007). Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc. Natl. Acad. Sci. U.S.A. 104, 20979-20984. doi: 10.1073/pnas.0707394104
173. Reglodi, D., Lubics, A., Tamas, A., Szalontay, L., and Lengvari, I. (2004). Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.Behav. Brain Res. 151, 303-312. doi: 10.1016/j.bbr.2003.09.007
174. Ricciotti, E., and FitzGerald, G. A. (2011). Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 31, 986-1000. doi: 10.1161/ATVBAHA.110.207449
175. Rissman, R. A., Poon, W. W., Blurton-Jones, M., Oddo, S., Torp, R., Vitek, M. P., et al. (2004). Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J. Clin. Invest. 114, 121-130. doi: 10.1172/JCI200420640
176. Ristic, G., Tsou, W. L., and Todi, S. V. (2014). An optimal ubiquitin-proteasome pathway in the nervous system: the role of deubiquitinating enzymes. Front. Mol. Neurosci. 7:72. doi: 10.3389/fnmol.2014.00072
177. Rockwell, P., Yuan, H. M., Magnusson, R., and Figueiredo-Pereira, M. E. (2000). Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE2. Arch. Biochem. Biophys. 374, 325-333. doi: 10.1006/abbi.1999.1646
178. Rodriguez-Grande, B., Blackabey, V., Gittens, B., Pinteaux, E., and Denes, A. (2013). Loss of substance P and inflammation precede delayed neurodegeneration in the substantia nigra after cerebral ischemia. Brain Behav. Immun. 29, 51-61. doi: 10.1016/j.bbi.2012.11.017
179. Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., et al. (2000). Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403, 103-108. doi: 10.1038/47520
180. Sandig, H., Pease, J. E., and Sabroe, I. (2007). Contrary prostaglandins: the opposing roles of PGD2 and its metabolites in leukocyte function. J. Leukoc. Biol. 81, 372-382. doi: 10.1189/jlb.0706424
181. Satoh, T., and Lipton, S. A. (2007). Redox regulation of neuronal survival mediated by electrophilic compounds.Trends Neurosci. 30, 37-45. doi: 10.1016/j.tins.2006.11.004
182. Scher, J. U., and Pillinger, M. H. (2005). 15d-PGJ2: the anti-inflammatory prostaglandin? Clin. Immunol. 114, 100-109. doi: 10.1016/j.clim.2004.09.008
183. Scher, J. U., and Pillinger, M. H. (2009). The anti-inflammatory effects of prostaglandins. J. Investig. Med. 57, 703-708. doi: 10.231/JIM.0b013e31819aaa76
184. Schneider, A., and Simons, M. (2013). Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders. Cell Tissue Res. 352, 33-47. doi: 10.1007/s00441-012-1428-2
185. Schulman, B. A., and Harper, J. W. (2009). Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat. Rev. Mol. Cell Biol. 10, 319-331. doi: 10.1038/nrm2673
186. Schuster, V. L. (1998). Molecular mechanisms of prostaglandin transport. Annu. Rev. Physiol. 60, 221-242. doi: 10.1146/annurev.physiol.60.1.221
187. Schuster, V. L. (2002). Prostaglandin transport. Prostaglandins Other Lipid Mediat. 68-69, 633-647. doi: 10.1016/S0090-6980(02)00061-8
188. Schwab, C., and McGeer, P. L. (2008). Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J. Alzheimers. Dis. 13, 359-369.
189. Selkoe, D. J. (2004). Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat. Cell Biol. 6, 1054-1061. doi: 10.1038/ncb1104-1054
190. Servidei, T., Morosetti, R., Ferlini, C., Cusano, G., Scambia, G., Mastrangelo, R., et al. (2004). The cellular response to PPARgamma ligands is related to the phenotype of neuroblastoma cell lines. Oncol. Res. 14, 345-354.
191. Shaik, J. S., Miller, T. M., Graham, S. H., Manole, M. D., and Poloyac, S. M. (2014). Rapid and simultaneous quantitation of prostanoids by UPLC-MS/MS in rat brain. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 945-946, 207-216. doi: 10.1016/j.jchromb.2013.11.041
192. Shanbhag, R., Shi, G., Rujiviphat, J., and McQuibban, G. A. (2012). The emerging role of proteolysis in mitochondrial quality control and the etiology of Parkinson's disease. Parkinsons Dis. 2012, 382175. doi: 10.1155/2012/382175
193. Shaw, L. M., Korecka, M., Clark, C. M., Lee, V. M., and Trojanowski, J. Q. (2007). Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat. Rev. Drug Discov. 6, 295-303. doi: 10.1038/nrd2176
194. Shibata, T., Kondo, M., Osawa, T., Shibata, N., Kobayashi, M., and Uchida, K. (2002). 15-deoxy-delta 12,14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes. J. Biol. Chem. 277, 10459-10466. doi: 10.1074/jbc.M110314200
195. Shibata, T., Yamada, T., Kondo, M., Tanahashi, N., Tanaka, K., Nakamura, H., et al. (2003). An endogenous electrophile that modulates the regulatory mechanism of protein turnover: inhibitory effects of 15-deoxy-delta(12,14)-prostaglandin J2 on proteasome. Biochemistry 42, 13960-13968. doi: 10.1021/bi035215a
196. Shimizu, M., Nakamura, H., Hirabayashi, T., Suganami, A., Tamura, Y., and Murayama, T. (2008). Ser515 phosphorylation-independent regulation of cytosolic phospholipase A2alpha (cPLA2alpha) by calmodulin-dependent protein kinase: possible interaction with catalytic domain A of cPLA2alpha. Cell Signal. 20, 815-824. doi: 10.1016/j.cellsig.2007.12.016
197. Shivers, K. Y., Nikolopoulou, A., Machlovi, S. I., Vallabhajosula, S., and Figueiredo-Pereira, M. E. (2014). PACAP27 prevents Parkinson-like neuronal loss and motor deficits but not microglia activation induced by prostaglandin J2.Biochim. Biophys. Acta 1842, 1707-1719. doi: 10.1016/j.bbadis.2014.06.020
198. Simmons, D. L., Botting, R. M., and Hla, T. (2004). Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56, 387-437. doi: 10.1124/pr.56.3.3
199. Smith, W. L., DeWitt, D. L., and Garavito, R. M. (2000). Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69, 145-182. doi: 10.1146/annurev.biochem.69.1.145
200. Smyth, E. M., Grosser, T., Wang, M., Yu, Y., and FitzGerald, G. A. (2009). Prostanoids in health and disease. J. Lipid Res. 50(Suppl.), S423-S428. doi: 10.1194/jlr.R800094-JLR200
201. Stamatakis, K., Sanchez-Gomez, F. J., and Perez-Sala, D. (2006). Identification of novel protein targets for modification by 15-deoxy-Delta12,14-prostaglandin J2 in mesangial cells reveals multiple interactions with the cytoskeleton. J. Am. Soc. Nephrol. 17, 89-98. doi: 10.1681/ASN.2005030329
202. Stoessl, A. J. (2014). Developments in neuroimaging: positron emission tomography. Parkinsonism Relat. Disord. 20(Suppl. 1), S180-S183. doi: 10.1016/S1353-8020(13)70042-7
203. Straus, D. S., and Glass, C. K. (2001). Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med. Res. Rev. 21, 185-210. doi: 10.1002/med.1006
204. Straus, D. S., Pascual, G., Li, M., Welch, J. S., Ricote, M., Hsiang, C. H., et al. (2000). 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc. Natl. Acad. Sci. U.S.A. 97, 4844-4849. doi: 10.1073/pnas.97.9.4844
205. Su, R. Y., Chi, K. H., Huang, D. Y., Tai, M. H., and Lin, W. W. (2008). 15-deoxy-Delta12,14-prostaglandin J2 up-regulates death receptor 5 gene expression in HCT116 cells: involvement of reactive oxygen species and C/EBP homologous transcription factor gene transcription. Mol. Cancer Ther. 7, 3429-3440. doi: 10.1158/1535-7163.MCT-08-0498
206. Subra, C., Grand, D., Laulagnier, K., Stella, A., Lambeau, G., Paillasse, M., et al. (2010). Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins. J. Lipid Res. 51, 2105-2120. doi: 10.1194/jlr.M003657
207. Surh, Y. J., Na, H. K., Park, J. M., Lee, H. N., Kim, W., Yoon, I. S., et al. (2011). 15-Deoxy-Delta(1)(2),(1)(4)-prostaglandin J(2), an electrophilic lipid mediator of anti-inflammatory and pro-resolving signaling. Biochem. Pharmacol. 82, 1335-1351. doi: 10.1016/j.bcp.2011.07.100
208. Suzuki, F., Hayashi, H., and Hayaishi, O. (1986). Transport of prostaglandin D2 into brain. Brain Res. 385, 321-328. doi: 10.1016/0006-8993(86)91079-6
209. Tai, H. H. (2011). Prostaglandin catabolic enzymes as tumor suppressors. Cancer Metastasis Rev. 30, 409-417. doi: 10.1007/s10555-011-9314-z
210. Tai, H. H., Cho, H., Tong, M., and Ding, Y. (2006). NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr. Pharm. Des. 12, 955-962. doi: 10.2174/138161206776055958
211. 2α levels in the rat hippocampus following kainic acid-induced seizures. Neuroscience 218, 295-304. doi: 10.1016/j.neuroscience.2012.05.013
212. Tassoni, D., Kaur, G., Weisinger, R. S., and Sinclair, A. J. (2008). The role of eicosanoids in the brain. Asia Pac. J. Clin. Nutr. 17(Suppl. 1), 220-228.
213. Taylor, E. B., and Rutter, J. (2011). Mitochondrial quality control by the ubiquitin-proteasome system. Biochem. Soc. Trans. 39, 1509-1513. doi: 10.1042/BST0391509
214. Teismann, P., Tieu, K., Choi, D. K., Wu, D. C., Naini, A., Hunot, S., et al. (2003). Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 100, 5473-5478. doi: 10.1073/pnas.0837397100
215. Uchida, K., and Shibata, T. (2008). 15-Deoxy-Delta(12,14)-prostaglandin J2: an electrophilic trigger of cellular responses. Chem. Res. Toxicol. 21, 138-144. doi: 10.1021/tx700177j
216. Upadhya, S. C., and Hegde, A. N. (2007). Role of the ubiquitin proteasome system in Alzheimer's disease. BMC Biochem. 8(Suppl. 1):S12. doi: 10.1186/1471-2091-8-S1-S12
217. Urade, Y., and Eguchi, N. (2002). Lipocalin-type and hematopoietic prostaglandin D synthases as a novel example of functional convergence. Prostaglandins Other Lipid Mediat. 68-69, 375-382. doi: 10.1016/S0090-6980(02)00042-4
218. Urade, Y., and Hayaishi, O. (2000). Prostaglandin D synthase: structure and function. Vitam. Horm. 58, 89-120. doi: 10.1016/S0083-6729(00)58022-4
219. Vasil'ev, Y. V., Tzeng, S. C., Huang, L., and Maier, C. S. (2014). Protein modifications by electrophilic lipoxidation products: adduct formation, chemical strategies and tandem mass spectrometry for their detection and identification. Mass Spectrom. Rev. 33, 157-182. doi: 10.1002/mas.21389
220. Vermeer, S. E., Prins, N. D., den, H. T., Hofman, A., Koudstaal, P. J., and Breteler, M. M. (2003). Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med. 348, 1215-1222. doi: 10.1056/NEJMoa022066
221. Vlad, S. C., Miller, D. R., Kowall, N. W., and Felson, D. T. (2008). Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70, 1672-1677. doi: 10.1212/01.wnl.0000311269.57716.63
222. Wall, S. B., Oh, J. Y., Diers, A. R., and Landar, A. (2012). Oxidative modification of proteins: an emerging mechanism of cell signaling. Front. Physiol. 3:369. doi: 10.3389/fphys.2012.00369
223. Wang, Z., Aris, V. M., Ogburn, K. D., Soteropoulos, P., and Figueiredo-Pereira, M. E. (2006). Prostaglandin J2 alters pro-survival and pro-death gene expression patterns and 26 S proteasome assembly in human neuroblastoma cells. J. Biol. Chem. 281, 21377-21386. doi: 10.1074/jbc.M601201200
224. Wilkinson, K. D., Deshpande, S., and Larsen, C. N. (1992). Comparisons of neuronal (PGP 9.5) and non-neuronal ubiquitin C-terminal hydrolases. Biochem. Soc. Trans. 20, 631-637.
225. Wilmer, W. A., Dixon, C., Lu, L., Hilbelink, T., and Rovin, B. H. (2001). A cyclopentenone prostaglandin activates mesangial MAP kinase independently of PPARgamma. Biochem. Biophys. Res. Commun. 281, 57-62. doi: 10.1006/bbrc.2001.4301
226. Wyss-Coray, T., and Mucke, L. (2002). Inflammation in neurodegenerative disease-a double-edged sword. Neuron35, 419-432. doi: 10.1016/S0896-6273(02)00794-8
227. Xu, S., and Venge, P. (2000). Lipocalins as biochemical markers of disease. Biochim. Biophys. Acta 1482, 298-307. doi: 10.1016/S0167-4838(00)00163-1
228. Yagami, T. (2006). Cerebral arachidonate cascade in dementia: Alzheimer's disease and vascular dementia. Curr. Neuropharmacol. 4, 87-100. doi: 10.2174/157015906775203011
229. Yamagata, K., Andreasson, K. I., Kaufmann, W. E., Barnes, C. A., and Worley, P. F. (1993). Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 11, 371-386. doi: 10.1016/0896-6273(93)90192-T
230. Yamamoto, Y., Takase, K., Kishino, J., Fujita, M., Okamura, N., Sakaeda, T., et al. (2011). Proteomic identification of protein targets for 15-deoxy-Delta(12,14)-prostaglandin J2 in neuronal plasma membrane. PLoS ONE 6:e17552. doi: 10.1371/journal.pone.0017552
231. Yazaki, M., Kashiwagi, K., Aritake, K., Urade, Y., and Fujimori, K. (2012). Rapid degradation of cyclooxygenase-1 and hematopoietic prostaglandin D synthase through ubiquitin-proteasome system in response to intracellular calcium level. Mol. Biol. Cell 23, 12-21. doi: 10.1091/mbc.E11-07-0623
232. Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S. M., Iwata, N., Saido, T. C., et al. (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351. doi: 10.1016/j.neuron.2007.01.010
233. Zagol-Ikapitte, I., Masterson, T. S., Amarnath, V., Montine, T. J., Andreasson, K. I., Boutaud, O., et al. (2005). Prostaglandin H(2)-derived adducts of proteins correlate with Alzheimer's disease severity. J. Neurochem. 94, 1140-1145. doi: 10.1111/j.1471-4159.2005.03264.x
234. Zhang, H. X., Tanji, K., Yoshida, H., Hayakari, M., Shibata, T., Mori, F., et al. (2010). Alteration of biochemical and pathological properties of TDP-43 protein by a lipid mediator, 15-deoxy-Delta(12,14)-prostaglandin J(2). Exp. Neurol. 222, 296-303. doi: 10.1016/j.expneurol.2010.01.007
235. Zhang, X., Wang, J. M., Gong, W. H., Mukaida, N., and Young, H. A. (2001). Differential regulation of chemokine gene expression by 15-deoxy-delta 12,14 prostaglandin J2. J. Immunol. 166, 7104-7111. doi: 10.4049/jimmunol.166.12.7104
236. Zhu, T., Gobeil, F., Vazquez-Tello, A., Leduc, M., Rihakova, L., Bossolasco, M., et al. (2006). Intracrine signaling through lipid mediators and their cognate nuclear G-protein-coupled receptors: a paradigm based on PGE2, PAF, and LPA1 receptors. Can. J. Physiol. Pharmacol. 84, 377-391. doi: 10.1139/y05-147
237. Ziebell, J. M., and Morganti-Kossmann, M. C. (2010). Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics 7, 22-30. doi: 10.1016/j.nurt.2009.10.016